Ashkelon, Israel

Integrity Applications

www.integrity-app.com
Ashkelon, Israel
SEARCH FILTERS
Time filter
Source Type

— The “Continuous Glucose Monitoring Systems Market - Medical Devices Pipeline Assessment, 2017” the report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Continuous Glucose Monitoring Systems pipeline products. Browse the 157 Tables and Figures, 70 Companies, Spread across 268 Pages Report Available at http://www.reportsnreports.com/contacts/discount.aspx?name=958615. Scope of the Report: Extensive coverage of the Continuous Glucose Monitoring Systems under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Continuous Glucose Monitoring Systems and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment / industry Companies are mentioned: A. Menarini Diagnostics S.r.l., Abbott Diabetes Care, Inc., Advanced Biosensors-Ohio, Llc, Advanced Medical Electronics Corporation, Arkal Medical, Inc., Bio-Impedance General Ltd., Biorasis, Inc., Biovotion AG, CALISTO MEDICAL, INC. (Inactive), Cardiff University Company, City, University of London, Columbia University, ConvaTec Group Plc, Cyber Medical Ltd., Debiotech SA, DexCom Inc, DirectSens GmbH, Echo Therapeutics Inc, Ecole Polytechnique Federale de Lausanne, eLutions Integrated, EyeSense GmbH, Flowsion A/S, Gili Medical Ltd, Globe Medical Tech Inc, and Others. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=958615. Continuous Glucose Monitoring Systems Market- Recent Developments : Mar 30, 2017: ConvaTec Expands Unomedical Manufacturing Technology Partnership with Medtronic Diabetes to Meet Growing Demand Mar 29, 2017: ConvaTec Group: Directorate changes Mar 28, 2017: Novo Acquires 19.95% Stake in Convatec from Nordic Capital and Avista for USD1.22 Billion Mar 28, 2017: ConvaTec: Proposed Directorate Changes Mar 27, 2017: Integrity Applications Board Appoints John Graham CEO and Chairman, Angela Strand Vice Chairman Mar 24, 2017: Medicare Announces Criteria Covering Dexcom G5 Mobile CGM for All People with Diabetes on Intensive Insulin Therapy Mar 21, 2017: Medtronic Prices Public Offering of 1.7% Notes Due 2019 for USD1 Billion Mar 21, 2017: Medtronic Prices Public Offering of 3.35% Notes Due 2027 for USD850 Million Mar 21, 2017: Medtronic Prices Public Offering of 4.625% Notes Due 2045 for USD150 Million Mar 21, 2017: Tenax Therapeutics Announces Year-End 2016 Financial Results and Provides Corporate Update Mar 14, 2017: PositiveID’s E-N-G Mobile Systems’ 2017 Bookings Through February Total $1.7 Million, Up More than 200% from Prior Quarter Mar 13, 2017: DexCom Appoints Richard Collins to Board of Directors Mar 08, 2017: Tandem Diabetes Care Reports 2016 Financial Results Continuous Glucose Monitoring Systems Market- Recent Developments for 2017, January and February is also mentioned. List of Tables Table 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development Table 2: Continuous Glucose Monitoring Systems - Pipeline Products by Segment Table 3: Continuous Glucose Monitoring Systems - Pipeline Products by Territory Table 4: Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path Table 5: Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date And more List of Figures Figure 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development Figure 2: Continuous Glucose Monitoring Systems - Pipeline Products by Territory Figure 3: Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path Figure 4: Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date Figure 5: Continuous Glucose Monitoring Systems - Ongoing Clinical Trials Complete Table of Content is Available at Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2017. About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/958615-continuous-glucose-monitoring-systems-medical-devices-pipeline-assessment-2017.html


News Article | August 2, 2017
Site: www.prnewswire.com

"This ongoing source of capital has provided us with resources to continue our progress towards a truly non-invasive solution to glucose measurement and, in addition supports the initial commercialization of GlucoTrack in Europe, as well as advances our clinical and regulatory efforts in the U.S. and China," stated John Graham, chairman and chief executive officer of Integrity Applications. "We appreciate the continued support of Andrew Garrett, our existing shareholders and welcome our new investors to the Company." About GlucoTrack® GlucoTrack® is a truly non-invasive monitoring device that rapidly measures and displays an individual's glucose level in about a minute without finger pricking or any pain. GlucoTrack® features a small sensor that clips to the earlobe and measures the user's glucose level using innovative and patented sensor technology. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The glucose results are stored in the device and used to project an estimated HbA1c level using a proprietary algorithm. The device can also display glucose values graphically, enabling the user to monitor glucose levels over time. GlucoTrack® has received CE Mark and KFDA approvals for type 2 diabetes and pre-diabetes, and is currently in the early stages of commercialization in Europe, South Korea and other geographies. GlucoTrack® is expected to begin clinical trials for United States FDA approval in late 2017. The product is currently experimental in the United States and is limited to investigational use only. About Integrity Applications, Inc. Integrity Applications was founded in 2001 and is focused on the design, development and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and pre-diabetes. The company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose measurements in about a minute without the pain, incremental cost, difficulty or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel. For more information, please visit www.integrity-app.com and www.glucotrack.com. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "expect", "plan" and "will" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications' actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications' results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications' filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC on March 30, 2017. The securities sold in the financing have not been registered under the United States Securities Act of 1933, as amended ("Securities Act"), and may not be offered or sold in the US absent registration or an applicable exemption from registration requirements. THIS PRESS RELEASE IS BEING ISSUED PURSUANT TO RULE 135C UNDER THE SECURITIES ACT AND DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE SECURITIES, NOR SHALL THERE BE ANY SALE OF THE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO THE REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF SUCH STATE. ANY OFFERING OF THE SECURITIES UNDER THE RESALE REGISTRATION STATEMENT WILL ONLY BE BY MEANS OF A PROSPECTUS.


Mr. Hauck is currently the Executive Director of The Getz Group, a privately owned pan-Asian trading company focused on healthcare, industrial products, consumer distribution and retailing. He previously held executive and director level positions at various companies including, ERM, Interpharma Investments Ltd, Invida Holdings, Target Worldwide Express, 3i plc, Springboard, and Business Health Group Ltd. Mr. Hauck also served as the CEO of Walsh International for eight years, where he led the company's IPO and eventual sale to IMS Health. Mr. Hauck commented, "I am delighted to be a part of Integrity Applications, which is changing the way glucose is monitored and diabetes is managed. I am excited about the prospects for the company's innovative non-invasive glucose monitoring technology, GlucoTrack, to transform diabetes management, but especially the potential to expand its offering to provide valuable data and insights to healthcare professionals. I look forward to working with the Integrity Applications team as the company continues its expansion." About GlucoTrack® GlucoTrack® is a truly non-invasive monitoring device that rapidly measures and displays an individual's glucose level in about a minute without finger pricking or any pain. GlucoTrack® features a small sensor that clips to the earlobe and measures the user's glucose level using innovative and patented sensor technology. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The glucose results are stored in the device and used for a projected HbA1c level using a proprietary algorithm. The device also displays the glucose values graphically allowing the user to monitor glucose over a period of time. GlucoTrack® has received CE Mark and KFDA approvals for type 2 diabetes and prediabetics, and is currently in the early stages of commercialization in Europe, South Korea and other geographies. GlucoTrack® is expected to begin clinical trials for United States FDA approval in late 2017. The product is currently experimental in the United States and is limited to investigational use only. About Integrity Applications, Inc. Integrity Applications was founded in 2001 and is focused on the design, development and commercialization of non-invasive glucose monitoring technologies for patients with diabetes and prediabetes. The company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel. For more information, please visit www.integrity-app.com and www.glucotrack.com. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "expect", "plan" and "will" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications' actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications' results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications' filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC on March 30, 2017. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/integrity-applications-glucotrack-innovator-expands-board-of-directors-with-the-appointment-of-michael-hauck-300463739.html


For more information, please visit the company website at www.integrity-app.com. About GlucoTrack® GlucoTrack® is a truly non-invasive monitoring device that rapidly measures and displays an individual's glucose level without finger pricking or any pain. GlucoTrack® features a small sensor that clips to the earlobe and measures the user's glucose level using innovative and patented sensor technology. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The derived glucose measurements are stored in the device and calculates a projected HbA1c level using a validated algorithm. The device also displays the glucose values graphically allowing the user to monitor glucose over a period of time. GlucoTrack® has received CE Mark and KFDA approvals for type 2 diabetes and prediabetics, and is currently in the early stages of commercialization in Europe, South Korea and other geographies. GlucoTrack® is expected to begin clinical trials for United States FDA approval in late 2017. The product is currently experimental in the United States and is limited to investigational use only. About Integrity Applications, Inc. Integrity Applications was founded in 2001 and is focused on the design, development and commercialization of non-invasive glucose monitoring technologies for patients with diabetes and pre-diabetes. The company has developed GlucoTrack®, a proprietary noninvasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel. For more information, please visit www.integrity-app.com and www.glucotrack.com. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "expect", "plan" and "will" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications' actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications' results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications' filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC on March 30, 2017. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/integrity-applications-to-present-glucotrack-data-at-american-diabetes-associations-77th-scientific-sessions-300462076.html


Previously, Mr. Podwalski was Senior Director of Global Commercial Effectiveness at Aventis Pharmaceuticals, where he designed and established leading practices in sales and marketing capabilities in the US, Europe, Asia and Latin America. While at Aventis, Mr. Podwalski provided global commercial leadership in the development of the global insulin business and improved pen delivery systems. Mr. Podwalski successfully launched Lantus and the Insulin Pen Delivery system in the United States, Germany, Japan and multiple other countries. This innovative basal insulin achieved peak sales of more than $9 billion, and has cumulative sales of more than $65 billion. Earlier in his career, Mr. Podwalski served in various capacities at Hoechst Marion Roussel Inc., including senior commercial leadership positions in both pharmaceutical and consumer healthcare products, most notably in diabetes. John Graham, CEO and Chairman of Integrity Applications, remarked, "We are excited to have David join the Integrity Applications' team. His extensive commercial and marketing background in diabetes, including driving sales and marketing for numerous new and relaunched products in the medical device industry, will be advantageous as we prepare to expand GlucoTrack commercial initiatives and implement strategies to capture a substantial portion of the market for non-invasive glucose monitoring in prediabetes and type 2 diabetes." Mr. Podwalski commented, "I am pleased to be joining Integrity Applications at such an exciting time in the company's growth. We are seeing the convergence of glucose monitoring technology and digital health for diabetes, and I am enthusiastic about the commercial opportunities for GlucoTrack. There is an urgent need to transform diabetes management and to slow the progression of the diabetes epidemic. We believe that GlucoTrack, a non-invasive and patient-friendly approach to glucose monitoring, has significant potential in these large and clinically important markets." About GlucoTrack® GlucoTrack® is a truly non-invasive monitoring device that rapidly measures and displays an individual's glucose level in about a minute without finger pricking or any pain. GlucoTrack® features a small sensor that clips to the earlobe and measures the user's glucose level using innovative and patented sensor technology. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The glucose results are stored in the device and used for a projected HbA1c level using a proprietary algorithm. The device also displays the glucose values graphically allowing the user to monitor glucose over a period of time. GlucoTrack® has received CE Mark and KFDA approvals for type 2 diabetes and prediabetics, and is currently in the early stages of commercialization in Europe, South Korea and other geographies. GlucoTrack® is expected to begin clinical trials for United States FDA approval in late 2017. The product is currently experimental in the United States and is limited to investigational use only. About Integrity Applications, Inc. Integrity Applications was founded in 2001 and is focused on the design, development and commercialization of non-invasive glucose monitoring technologies for patients with diabetes and prediabetes. The company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel. For more information, please visit www.integrity-app.com and www.glucotrack.com. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "expect", "plan" and "will" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications' actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications' results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications' filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC on March 30, 2017. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/integrity-applications-glucotrack-innovator-names-david-podwalski-as-chief-commercial-officer-300470895.html


News Article | June 19, 2017
Site: www.businesswire.com

LOS ANGELES--(BUSINESS WIRE)--LinQuest Corporation is proud to announce that the Air Force Space and Missile Systems Center (SMC) at Los Angeles Air Force Base in El Segundo, CA has recently awarded the One Acquisition Solution for Integrated Services (OASIS) Management Operations, Enterprise Architecting, Test and Validation, Integration, and Systems Engineering (METIS) contract to LinQuest Corporation. For this procurement, LinQuest teamed with A2 Systems Engineering, AT&T Government Solutions, Inc., Booz Allen Hamilton (BAH), ExoAnalytic Solutions, Integrity Applications Incorporated (IAI), Jackson and Tull, and Science Applications International Corporation (SAIC). The LinQuest Team provides SETA support to the Advanced Systems and Development Directorate (SMC/AD) and assists with a wide range of responsibilities including: future requirements; development planning; architecting; science and technology; investment planning; advanced hypersonics; mission planning; mission management; the space test program; the rocket systems launch program; the multi-mission satellite operations center; and planning, programming, budgeting, and execution support at the Pentagon. “The win of the METIS contract confirms our team’s capabilities and validates the government’s confidence in our abilities to perform the broad spectrum of tasks that are necessary to assist SMC/AD in shaping the future of Space and in being the premier center for advanced systems and developmental planning,” said Christopher Beres, Vice President of LinQuest’s Space Systems Engineering and Integration business group. Dr. Leon Biederman, LinQuest’s President and CEO, stated, “The AD/METIS contract places LinQuest and its teammates in a position of thought leadership to support SMC at a moment of significant change. We expect the AD/METIS team to assist SMC substantiate the Air Force’s Space Enterprise vision into new programs and initiatives.” LinQuest provides our DoD, IC, and other customers cost-effective technical services and solutions for critical national security capabilities focused on the convergence of C4ISR, information, and cyber systems. LinQuest delivers performance excellence, from initial concept to operational capability, providing thought leadership, innovation, and engineering process discipline across the Enterprise lifecycle. More information can be found at the company’s website at www.linquest.com.


Patent
Integrity Applications | Date: 2016-12-21

A hinge pin joint for facilitating precise separation of the jaws of a spring clip, including a base cylinder with a threaded bore, supports extending laterally out from the base cylinder, pin supports capable of pivoting, and stabilizing wings extending from the pin supports. In one embodiment, the capability of pivoting includes pins that are integral with the pin supports and which extend out laterally from the pin support. An alternate embodiment includes aligned opening in the pin supports into which pins may be inserted. At least one stopper may be disposed on at least one of the pin supports for supporting the upper shell. The stabilizing wings are configured as plates that are semi-rigidly secured in guide structures within the lower shell.


Patent
Integrity Applications | Date: 2014-03-05

A hinge pin joint for facilitating precise separation of the jaws of a spring clip, comprising: a base cylinder with a threaded bore; supports extending laterally out from said base cylinder; pin supports having means for pivoting; and stabilizing wings extending from the pin supports. In one embodiment, the means for pivoting includes pins that are integral with the pin supports and which extend out laterally from the pin support. An alternate embodiment comprises aligned openings in the pin supports into which pins may be inserted. At least one stopper may be disposed on at least one of the pin supports for supporting the upper shell. The stabilizing wings are configured as plates that are semi-rigidly secured in guide structures within the lower shell.


Patent
Integrity Applications | Date: 2014-08-20

In order to, increase the accuracy of non-invasive glucose measurement, the device uses a combination of three non-invasive methods: ultrasonic, electromagnetic and thermal. The non-invasive glucose monitor comprises a Main Unit, which drives three different sensor channels (one per technology), located on an external unit configured as an ear clip attached to the subjects ear lobe. To effect the ultrasonic channel, ultrasonic piezo elements are positioned on opposing portions of the ear clip and thus opposite sides of the ear lobe. For implementation of the electromagnetic channel, capacitor plates are positioned on opposing portions of the ear clip and the ear lobe serves as the dielectric. The thermal channel includes a heater and a sensor positioned on the ear clip in close juxtaposition to the ear lobe.


Patent
Integrity Applications | Date: 2012-07-03

In order to increase the accuracy of non-invasive glucose measurement, the device uses a combination of three non-invasive methods: ultrasonic, electromagnetic and thermal. The non-invasive glucose monitor comprises a Main Unit, which drives three different sensor channels (one per technology), located on an external unit configured as an ear clip attached to the subjects ear lobe. To effect the ultrasonic channel, ultrasonic piezo elements are positioned on opposing portions of the ear clip and thus opposite sides of the ear lobe. For implementation of the electromagnetic channel, capacitor plates are positioned on opposing portions of the ear clip and the ear lobe serves as the dielectric. The thermal channel includes a heater and a sensor positioned on the ear clip in close juxtaposition to the ear lobe.

Loading Integrity Applications collaborators
Loading Integrity Applications collaborators